Male/Female | 40/39 |
Age of onset (mean ± SD, range) | 16±12 (2–68) |
Age of diagnosis (mean ± SD, range) | 27±13 (7–70) |
Family history of FMF | 47% |
Disease follow-up duration (mo) | 66±85 (6–480) |
Time to diagnosis (mo) | 121±136 (2–576) |
Family history of amyloidosis (%) | 18% |
Arthritis at presentation (%) | 60% |
MEFV variations (n=46) | M694V, 68% |
V726A, 10% | |
M680I, 15% | |
Others, 7% | |
IL-1 inhibitors n (%) | 43 (54%) |
Patients on hemodialysis | 7 (9%) |
Renal Transplantation n (%) | 17 (21%) |
High CRP levels in attack-free periods n (%) | 31 (39%) |